BGIM
AGRX

Brandywine Global Investment Management’s Agile Therapeutics AGRX Stock Holding History

Brandywine Global Investment Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-102
Closed -$426K – 742
2021
Q1 		$426K Sell
102
-2
-2% -$10.8K ﹤0.01% 602
2020
Q4 		$595K Buy
+104
New +$612K ﹤0.01% 551

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brandywine Global Investment Management's AGRX Position: Q2 2021 in Review

Brandywine Global Investment Management sold out of Agile Therapeutics (AGRX) in Q2 2021, closing a stake of 102 shares — an estimated $426K sold.

Brandywine Global Investment Management first reported a position in AGRX in Q4 2020 and held it in 2 quarters. The position peaked at $595K in Q4 2020. 64 funds tracked by Wall St. Rank hold AGRX as of Q2 2021.

  • Brandywine Global Investment Management reported no remaining Agile Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Brandywine Global Investment Management sold 102 Agile Therapeutics shares in Q2 2021, an estimated $426K.
  • Brandywine Global Investment Management first reported a position in Agile Therapeutics in Q4 2020 and held it in 2 quarters.
  • Brandywine Global Investment Management's Agile Therapeutics position peaked at $595K in Q4 2020.
  • 64 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2021.

Based on Brandywine Global Investment Management's 13F filing for Q2 2021, filed 13 Aug 2021.